This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (12)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Cardiovascular System  • Thrombolysis  • Alert me on articles by topic

Yes

Armin J. Grau, MD; Werner Hacke, MD
From the Neurology Department, University of Heidelberg, Heidelberg, Germany.

Arch Neurol. 1999;56:1159-1160.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRAVENOUS (IV) heparin was frequently considered a treatment option in acute ischemic stroke. However, only limitation of thrombus growth and facilitation of spontaneous endogenous thrombolysis are reasons to believe in its value in treating the index stroke. Most clinicians nowadays agree that the use of heparin, either IV or subcutaneously (SC), prevents deep venous thrombosis and pulmonary embolism.¹ However, the question remains whether heparin does prevent recurrent stroke. In view of the potential hemorrhagic complications and heparin-induced thrombocytopenia, early treatment with IV heparin has always been a matter of controversy. In 1994, the Stroke Council of the American Heart Association did not recommend heparin because data about safety and efficacy were insufficient and conflicting.¹ Nevertheless, in the absence of other acute treatment options and with proved primary and secondary preventive effects of oral anticoagulation in cardioembolic stroke, IV heparin was frequently applied in . . . [Full Text of this Article]

RELATED ARTICLES

Is There Still a Role for Intravenous Heparin in Acute Stroke?: No
Peter Sandercock
Arch Neurol. 1999;56(9):1160-1162.
EXTRACT | FULL TEXT  

Intravenous Heparin in Acute Stroke
Vladimir Hachinski
Arch Neurol. 1999;56(9):1162.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Albers et al.
Chest 2008;133:630S-669S.
ABSTRACT | FULL TEXT  

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?
O'Donnell et al.
Stroke 2006;37:452-455.
ABSTRACT | FULL TEXT  

Determinants of IV heparin treatment in patients with ischemic stroke
Schmidt et al.
Neurology 2004;63:2407-2409.
ABSTRACT | FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Albers et al.
Chest 2004;126:483S-512S.
ABSTRACT | FULL TEXT  

"Computed Tomography-Negative" Intracerebral Hemorrhage: Case Report and Implications for Management
Packard et al.
Arch Neurol 2003;60:1156-1159.
ABSTRACT | FULL TEXT  

Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke * Editorial Comment
Castellanos et al.
Stroke 2003;34:40-46.
ABSTRACT | FULL TEXT  

Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke
Adams
Stroke 2002;33:856-861.
ABSTRACT | FULL TEXT  

Treatment of Acute Ischemic Stroke
Brott and Bogousslavsky
NEJM 2000;343:710-722.
FULL TEXT  

More on Heparin in Stroke
JWatch General 1999;1999:2-2.
FULL TEXT